ProPhase Labs (NASDAQ:PRPH – Get Free Report) is expected to be releasing its earnings data before the market opens on ...

Shares of ProPhase Labs, Inc. (PRPH) have been struggling lately and have lost 21% over the past week. However, a hammer ...

ProPhase Labs, Inc. GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer ...

I n a challenging market environment, ProPhase Labs Inc. (PRPH) stock has touched a 52-week low, dipping to $0.56, marking a stark contrast to its 52-week high of $7.48. This price level reflects ...

ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced that Ted Karkus, CEO, will be presenting at this ...

ProPhase Labs (PRPH) provides a Company update and schedules a conference call. Following the hiring of Stu Hollenshead, several new strategic opportunities have emerged for the Company to ...

ProPhase Labs, Inc. announced that CEO Ted Karkus will present at the upcoming Investor Summit Virtual on March 11, 2025, at 1:30 P.M. ET, offering investors insights into the company's operations ...

ProPhase Labs (NASDAQ:PRPH) stock rose +12% Tuesday premarket as it named Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company’s expansion into consumer-centered ...

ProPhase Labs (PRPH) is focused on immediate cash generation through two key initiatives: strategic alternatives including a potential sale of its genomics assets and the aggressive collection of ...

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare ...

The exact molecular functions of Polo-like kinase 1 (PLK1) in mitotic prophase are not fully understood. This study shows ...